NEU | Small Caps

Neuren Pharmaceuticals ASX NEU FDA grants orphan drug designation Phelan-McDermid Pitt Hopkins syndrome

Neuren Pharma granted orphan drug status for treatment of Phelan-McDermid, Pitt Hopkins and Angelman syndromes

October 16, 2019

A drug developed by Neuren Pharmaceuticals (ASX: NEU) to treat debilitating childhood neurodevelopmental disorders has been granted orphan drug designation by the US Food and Drug Administration. D...

Read more

Neuren Pharmaceuticals ASX NEU NNZ-2591 Pitt Hopkins Angelman syndrome model

Neuren’s NNZ-2591 drug candidate alleviates Pitt Hopkins and Angelman syndrome symptoms

May 17, 2019

Neuren Pharmaceuticals (ASX: NEU) has revealed positive pre-clinical results for its NNZ-2591 drug candidate in treating Pitt Hopkins and Angelman syndromes. According to Neuren, its NNZ-2591 drug ...

Read more

Neuren Pharmaceuticals ASX NEU ACADIA Pharma trofinetide Rett Syndrom licence US

Neuren Pharmaceuticals receives first payment in Rett drug licence deal

August 22, 2018

Neuren Pharmaceuticals (ASX: NEU) has received the first US$10 million payment under a recently announced licence deal with US-based ACADIA Pharmaceuticals to develop its drug trofinetide to treat pat...

Read more

Neuren Pharmaceuticals NEU Phase 3 FDA approval Rett syndrome

FDA greenlights Neuren Pharmaceuticals to kick-off next trial for Rett drug

October 13, 2017

Melbourne-based Neuren Pharmaceuticals (ASX: NEU) reported the US Food and Drug Administration has given the greenlight for the company to start phase three trials for its drug trofinetide, which is u...

Read more

RECENT POSTS

Afterpay ASX APT capital raising sell down BNPL

Afterpay to stage $800m raising, co-founders sell-down 4m shares

July 7, 2020

Marquee Resources ASX MQR Fyfehill West Spargoville Project gold nickel

Marquee Resources to acquire West Spargoville project to capitalise on gold price increase

July 7, 2020

Image Resources will sell 100,000t of heavy mineral concentrate at current market prices to existing offtake partners.

Image Resources sells excess heavy mineral concentrate from Boonanarring at current market prices

July 7, 2020

eSense-Lab ASX ESE Blue Science Solutions LLC terpenes based sanitiser products

eSense-Lab signs $10 million agreement for sales of terpene sanitisers into US market

July 7, 2020

STOCK SUMMARY

INVESTOR TOOLS

FOLLOW US

HOT TOPICS

ASX blockchain delay launch settlement technology CHESS distributed ledger technology DLT

ASX delays launch of blockchain settlement technology

July 6, 2020

2020 2021 financial year extreme volatility ASX Australia stock market 2019

Weekly review: new financial year brings relief from extreme volatility

July 4, 2020

Australia record budget deficit surplus COVID-19 coronavirus Scott Morrison government

Record budget deficits loom for Australia as debt begins to soar

July 4, 2020

TRENDING POSTS

China counterfeit gold scandal Wuhan Kingold Jewelry fake bars loans

China in counterfeit gold scandal as Wuhan company uses fake bars to gain $4.1bn in loans

Biotron ASX BIT HIV immune system evasion BIT225 AIDS

Biotron’s BIT225 drug show to enhance body’s immune response to HIV

Redstone Resources ASX RDS West Musgrave Project copper sulphides EM5 Tollu

Redstone Resources pulls up 95m thick copper intersection at Musgrave

ASX blockchain delay launch settlement technology CHESS distributed ledger technology DLT

ASX delays launch of blockchain settlement technology

Australia record budget deficit surplus COVID-19 coronavirus Scott Morrison government

Record budget deficits loom for Australia as debt begins to soar

Sezzle ASX SZL 1 billion annual merchant sales COVID-19

Sezzle on course to generate over $1 billion in annual merchant sales

Afterpay ASX APT capital raising sell down BNPL

Afterpay to stage $800m raising, co-founders sell-down 4m shares

Bellevue Gold ASX BGL maiden indicated resource Western Australia

Bellevue Gold transitions from explorer to project developer with high-grade indicated resource

Small Caps is Australia's #1 site for news & information on ASX listed small cap companies.

Small Caps and affiliated companies accept no responsibility for any claim, loss or damage as a result of information provided or its accuracy. The information provided on this site is general in nature, not financial product advice, see a financial expert before making any investment decision. Your personal objectives, financial situation or needs have not been taken into consideration. There may be a conflict of interest present with commercial arrangements with companies and/or stock held. Small Caps or an associate may receive a commission for funds raised.